Eton Pharmaceuticals Inc
NASDAQ:ETON

Watchlist Manager
Eton Pharmaceuticals Inc Logo
Eton Pharmaceuticals Inc
NASDAQ:ETON
Watchlist
Price: 12.66 USD 1.28%
Market Cap: 327.1m USD
Have any thoughts about
Eton Pharmaceuticals Inc?
Write Note

Eton Pharmaceuticals Inc
Investor Relations

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Mr. Sean E. Brynjelsen
President, CEO & Director
No Bio Available
Mr. James R. Gruber CPA
CFO, Treasurer & Secretary
No Bio Available
Mr. David C. Krempa
Chief Business Officer
No Bio Available
Danka Radosavljevic
Senior Vice President of Quality & Operations
No Bio Available
Mr. Scott Grossenbach
Vice President of Sales Operations
No Bio Available
Mr. Kevin Guthrie
Executive VP of Commercial Operations
No Bio Available

Contacts

Address
ILLINOIS
Deer Park
21925 W Field Pkwy Ste 235
Contacts
+18477877361.0
etonpharma.com